In thyroid cancer patients after surgery, a single dose of radioactive iodine targeted to residual thyroid tissue successfully eliminated detectable disease in 85% of cases, with nearly 80% achieving no detectable thyroid protein and no visible tumors, allowing for accurate future monitoring.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether disease status-guided radioiodine remnant ablation achieves higher success rates than risk-stratification-guided ablation across multiple studies.
A systematic review and meta-analysis of all prospective studies comparing success rates (Tgon < 0.2 ng/mL and negative imaging) of radioiodine remnant ablation using disease status (Tgoff + imaging) versus ATA risk stratification, including only studies with standardized dosing and follow-up protocols.
Whether disease status-guided radioiodine remnant ablation achieves higher success rates than risk-stratification-guided ablation in patients with intermediate-risk thyroid cancer.
A multicenter, double-blind RCT of 400 patients with intermediate-risk DTC, randomized to receive RRA guided by disease status (Tgoff + imaging) or by 2015 ATA risk stratification, with primary endpoint of success rate (Tgon < 0.2 ng/mL and negative imaging) at 12 months.
Whether disease status-guided radioiodine remnant ablation achieves consistent success rates across diverse clinical settings and patient subgroups.
A prospective multicenter cohort study of 800 patients with DTC undergoing RRA, stratified by age, tumor size, and Tgoff level, measuring success rate (Tgon < 0.2 ng/mL and negative imaging) at 12 months and correlating with baseline characteristics.
Whether patients with failed remnant ablation were more likely to have been assigned therapy based on risk stratification rather than disease status.
A case-control study comparing 150 patients with failed RRA (Tgon ≥ 0.2 ng/mL or structural disease) to 300 matched controls with successful ablation, assessing whether their initial assignment was based on disease status or ATA risk stratification.
The proportion of patients achieving excellent response after radioiodine remnant ablation at a single time point.
A cross-sectional analysis of 500 patients with DTC who underwent RRA, measuring Tgon levels and imaging findings at 12 months post-treatment to classify response as excellent, indeterminate, or incomplete.